FLGT - Fulgent Genetics Inc Stock Price, Fair Value and News

23.65USD+0.66 (+2.87%)Market Closed

Market Summary

USD23.65+0.66

Market Closed

2.87%

FLGT Stock Price

View Fullscreen

FLGT RSI Chart

FLGT Valuation

Market Cap

707.7M

Price/Earnings (Trailing)

-4.26

Price/Sales (Trailing)

2.46

EV/EBITDA

-4.59

Price/Free Cashflow

39.43

FLGT Price/Sales (Trailing)

FLGT Profitability

Operating Margin

37.47%

EBT Margin

-58.15%

Return on Equity

-14.7%

Return on Assets

-13.51%

Free Cashflow Yield

2.54%

FLGT Fundamentals

FLGT Revenue

Revenue (TTM)

287.5M

Rev. Growth (Yr)

-2.54%

Rev. Growth (Qtr)

-8.54%

FLGT Earnings

Earnings (TTM)

-166.1M

Earnings Growth (Yr)

12.24%

Earnings Growth (Qtr)

89.48%

Breaking Down FLGT Revenue

Last 7 days

4.3%

Last 30 days

12.7%

Last 90 days

14.3%

Trailing 12 Months

-41.3%

How does FLGT drawdown profile look like?

FLGT Financial Health

Current Ratio

5.09

FLGT Investor Care

Shares Dilution (1Y)

0.75%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	287.5M	0	0	0
2023	364.9M	307.4M	286.4M	289.2M
2022	953.4M	869.8M	702.6M	619.0M
2021	773.4M	909.7M	1.0B	992.6M
2020	34.9M	43.8M	135.1M	421.7M
2019	22.1M	25.1M	29.8M	32.5M
2018	18.1M	18.8M	20.0M	21.4M
2017	20.1M	20.8M	20.3M	18.7M
2016	11.4M	13.2M	15.3M	18.3M
2015	3.4M	5.4M	7.5M	9.6M
2014	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

CEO	Mr. Ming Hsieh
WEBSITE	fulgentgenetics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	1012

Fulgent Genetics Inc Frequently Asked Questions

What is the ticker symbol for Fulgent Genetics Inc? What does FLGT stand for in stocks?

FLGT is the stock ticker symbol of Fulgent Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fulgent Genetics Inc (FLGT)?

As of Thu Jul 25 2024, market cap of Fulgent Genetics Inc is 687.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FLGT stock?

You can check FLGT's fair value in chart for subscribers.

Is Fulgent Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether FLGT is over valued or under valued. Whether Fulgent Genetics Inc is cheap or expensive depends on the assumptions which impact Fulgent Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FLGT.

What is Fulgent Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, FLGT's PE ratio (Price to Earnings) is -4.14 and Price to Sales (PS) ratio is 2.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FLGT PE ratio will change depending on the future growth rate expectations of investors.